AstraZeneca India gets CDSCO approval for 'Palivizumab' preventive therapy against respiratory syncytial virus https://ift.tt/L2ckiMY

RSV poses a significant global public health challenge, particularly affecting children, and stands as the second most common cause of death in infants under one year of age, following only malaria. The World Health Organisation (WHO) estimates that RSV accounts for over 60 per cent of acute respiratory infections in children and more than 80 per cent in infants under one year old.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/Yy9sBOk